⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now about SMA.

SMA is treatable — and outcomes depend heavily on how early treatment starts. Four FDA-approved disease-modifying therapies (Zolgensma, Itvisma, Spinraza, Evrysdi) have fundamentally changed what SMA looks like over the past decade. The earlier they are started, the better motor neurons are preserved.
Newborn screening for SMA is now performed in all 50 U.S. states (Utah was the first state to add SMA to its newborn screen, in January 2018). Babies identified before symptoms appear can often be treated in the first weeks of life and reach milestones — including walking — that were once considered impossible for SMA Type 1.
There are four FDA-approved SMN-targeted therapies, and each works differently: Zolgensma is a one-time IV gene therapy (under age 2); Itvisma is a one-time intrathecal gene therapy (age 2 and older); Spinraza is given by lumbar puncture every 4 months; and Evrysdi is a daily liquid taken by mouth at home. There is no single “best” choice — the right one depends on your child’s age, weight, SMN2 copy number, spinal anatomy, and family circumstances.
SMN2 copy number is a powerful prediction tool. Children with fewer SMN2 copies (1–2) typically have more severe disease without treatment; children with 3–4 copies tend to be milder. This number guides treatment timing — especially when a baby is diagnosed before symptoms.
SMN-targeted therapy alone is not enough. Multidisciplinary care — respiratory support, nutrition, physical and occupational therapy, orthopedic monitoring — remains essential. The medications keep motor neurons alive; the team keeps the rest of the body working.
Cost and access are real barriers. Zolgensma in the U.S. carries a list price near $2.1 million; Spinraza and Evrysdi cost hundreds of thousands of dollars per year. Specialty pharmacy navigation, manufacturer patient assistance programs, and Medicaid waivers are often essential. Don’t go it alone — ask your care team for a social worker and a financial navigator early.
SMA is no longer just a pediatric disease. Adults with SMA Types 2, 3, and 4 are now eligible for and benefiting from these therapies. If you or a family member was diagnosed before treatments existed, it is worth re-engaging with a neuromuscular specialist.
You are not alone. Cure SMA, the Muscular Dystrophy Association (MDA), SMA Europe, and TREAT-NMD maintain large, active communities. Specialized neuromuscular clinics — including the MDA Care Center at the University of Utah and the neuromuscular program at Primary Children’s Hospital — coordinate care across specialists.

▼ Collapse

Understanding Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic condition that affects the motor neurons — the nerve cells in the spinal cord that send signals from the brain to the muscles. When these motor neurons don’t work properly, muscles weaken and shrink (atrophy), which can affect the ability to move, swallow, and breathe.

SMA happens because of a problem with a gene called SMN1. This gene tells the body how to make a protein called “survival motor neuron” (SMN), which motor neurons need to stay healthy. In SMA, both copies of SMN1 are missing or damaged, and the body cannot make enough SMN protein on its own. A nearby gene called SMN2 makes a small amount of working SMN protein — usually not enough, but more SMN2 copies generally mean a milder form of the disease.

The big picture has changed. A decade ago, SMA Type 1 was the leading genetic cause of infant mortality, and there was no specific treatment. Today, with newborn screening and four approved disease-modifying therapies, many children diagnosed and treated early grow up reaching motor milestones — including sitting, standing, and walking — that were once considered out of reach.

SMA has traditionally been divided into five types based on the age symptoms first appear and the highest motor milestone achieved without treatment:

Type 0 — Begins before birth. The most severe form, with profound weakness at birth and life-threatening breathing problems.
Type 1 (Werdnig-Hoffmann disease) — Symptoms before 6 months of age. Without treatment, infants typically cannot sit unsupported. Historically, most children did not survive past age 2 without ventilator support.
Type 2 — Symptoms between 6 and 18 months. Children can sit but cannot walk unsupported without treatment.
Type 3 (Kugelberg-Welander disease) — Symptoms after 18 months. Children can walk, but may lose that ability over time.
Type 4 — Adult-onset, generally after age 30. The mildest form.

Important context: These types were defined before disease-modifying therapies existed. With early treatment — especially pre-symptomatic treatment after newborn screening — a child who would have had Type 1 may now develop a motor course much closer to a healthy peer. Your neuromuscular specialist may classify children today by SMN2 copy number and functional status (“sitter,” “walker,” “non-sitter”) rather than strictly by type.

SMA affects roughly 1 in 10,000 live births. It is autosomal recessive, meaning a child must inherit one non-working SMN1 gene from each parent to have the disease. About 1 in 40 to 1 in 60 people in the general population is a carrier — they have one non-working copy but are healthy. Carriers do not have SMA themselves but can pass the gene to their children.

Carrier frequency may be higher in populations with higher rates of consanguinity, including some Middle Eastern, North African, and South Asian populations.

What does my child’s SMN2 copy number tell us about what to expect?
If we’re here because of newborn screening, how quickly do we need to make a treatment decision?
What does “pre-symptomatic” mean, and is my baby still in that window?
Will my child be classified by SMA “type,” or are you using a different framework now?
Should other family members be tested as carriers?

Diagnosis & Genetics: Understanding Your Test Results

SMA is diagnosed by a genetic blood test that looks for a missing or non-functional SMN1 gene and counts the number of SMN2 copies. This is usually triggered in one of three ways:

Newborn screening — A few drops of blood from the baby’s heel screen for SMA along with dozens of other conditions. A positive screen always requires a confirmatory genetic test.
Symptom-driven testing — A baby, child, or adult develops weakness, and a doctor orders SMN1/SMN2 testing as part of the workup.
Carrier or prenatal testing — Parents are tested before or during pregnancy because of family history or routine carrier screening.

Why SMN2 copy number matters. Children with 2 SMN2 copies almost always develop severe (Type 1-like) disease without treatment. Those with 3 copies are usually intermediate. Those with 4+ copies often have milder disease that may not appear until later in childhood or adulthood — but treatment decisions for these children involve more nuance, because some may never become symptomatic.

🕑 Your first-month action clock (positive newborn screen or new diagnosis). Earlier treatment preserves more motor neurons, so this calendar is deliberately fast — presymptomatic treatment gives the best results. Confirm each step’s timing with your neuromuscular team; a baby with 2 SMN2 copies moves fastest.

Within the first week (days 1–7): Confirmatory SMN1 genetic test drawn (to confirm deletion of both copies) and SMN2 copy number ordered; urgent neuromuscular referral placed; anti-AAV9 antibody titer drawn if gene therapy is being considered.
Ask: "Is the deletion of both SMN1 copies confirmed, and exactly how many SMN2 copies does my child have?"
Within two weeks (by day 14): Baseline motor exam (CHOP-INTEND), swallow and breathing assessment, and a family treatment meeting to choose among the FDA-approved therapies.
Ask: "Given the SMN2 copy number and my child’s weight and age, which therapy is fastest to start, and are we still in the pre-symptomatic window?"
In the first month (by day 30): Disease-modifying therapy started — for infants with 2–3 SMN2 copies, most centers aim to begin within the first 2–6 weeks of life.
By month 3: The therapy-specific monitoring is underway (see the treatment and safety sections) and the multidisciplinary team — respiratory, nutrition, physical and occupational therapy, orthopedics — is scheduled.

A positive newborn screen for SMA is a neurogenetic emergency — especially for babies with 2 SMN2 copies, who can develop irreversible motor neuron loss within weeks. Expect the following sequence, usually within days:

Urgent referral to a pediatric neurologist or neuromuscular specialist (in Utah, typically Primary Children’s Hospital or the University of Utah).
Confirmatory testing — A second blood sample is sent for definitive SMN1/SMN2 analysis, often through ARUP Laboratories in Salt Lake City.
Baseline assessment — Motor exam (CHOP-INTEND for infants), breathing assessment, swallow evaluation, and bloodwork.
Treatment decision — Family meeting with the neuromuscular team to choose among Zolgensma, Spinraza, and Evrysdi based on SMN2 copy number, weight, anti-AAV9 antibody status (for Zolgensma), and family values.
Treatment initiation — Ideally within the first 2–6 weeks of life for babies with 2–3 SMN2 copies.

This pace can feel disorienting. Bringing a notebook, a second listener, and a list of questions to each appointment helps.

Not everyone with SMA is diagnosed as a newborn. Symptoms that prompt testing later include:

An infant or toddler not meeting motor milestones (delayed sitting, not walking by 15–18 months)
A school-age child with progressive weakness, frequent falls, or trouble climbing stairs
A teen or adult with unexplained proximal weakness (thighs, hips, shoulders), muscle twitching (fasciculations), or hand tremor

Adult diagnosis often takes years because SMA Type 3 and Type 4 can look like other neuromuscular conditions. If you have unexplained proximal weakness, ask whether SMN1/SMN2 testing has been done — it’s a simple blood test, and treatment is available for adults.

If your child is diagnosed with SMA, both parents are carriers. Each future pregnancy carries a 1 in 4 chance of having SMA, a 1 in 2 chance of being an unaffected carrier, and a 1 in 4 chance of inheriting two normal copies. Genetic counseling can help with:

Understanding inheritance for siblings and extended family
Carrier testing for adult siblings, aunts, uncles, and cousins who may be planning families
Prenatal testing options (chorionic villus sampling, amniocentesis) in future pregnancies
Preimplantation genetic testing (PGT) with IVF to select unaffected embryos
Emotional support for the implications of carrier status

How many SMN2 copies does my child have, and what does that mean for what to expect?
Was the SMN1 result a deletion of both copies, or one deletion and one mutation? Does that matter for treatment?
Should I be tested? Should my partner? Other relatives?
If we want more children, what are our options for prenatal or preimplantation testing?
Will I get a written copy of the genetic test results to keep?
Is there a research registry (like Cure SMA or TREAT-NMD) we can join?

SMN-Targeted Treatments: The Four Approved Therapies

There are four FDA-approved disease-modifying therapies for SMA. All four increase the amount of SMN protein available to motor neurons, but they do so in different ways and through very different routes of administration. None of them is a cure — they slow, halt, or in some cases largely prevent the progression of SMA, but they do not regrow motor neurons that have already been lost. This is why earlier treatment matters so much.

Time is motor neurons. Motor neurons that have died cannot be brought back. Every week of treatment delay in a symptomatic infant with severe SMA can mean lost function that doesn’t return. This is why newborn screening and pre-symptomatic treatment have been such transformative changes in SMA care.

FDA-label doses at a glance. The exact dose is set and monitored by your team; these are the label-specified amounts, so you can recognize them on prescriptions and infusion orders.

Spinraza (nusinersen), intrathecal: per the FDA label, 12 mg per dose — four loading doses (about day 0, 14, 28, and 58), then 12 mg every 4 months for life. A higher-dose schedule (FDA-approved March 2026) uses two 50 mg loading doses 14 days apart, then 28 mg every 4 months.
Evrysdi (risdiplam), oral, once daily (FDA label, by weight and age): under 2 months, 0.15 mg/kg; 2 months to under 2 years, 0.20 mg/kg; age 2 or older and under 20 kg, 0.25 mg/kg; age 2 or older and 20 kg or more, 5 mg once daily.
Zolgensma (onasemnogene abeparvovec), one-time IV: a weight-based gene-therapy dose given once. The FDA label also directs a systemic steroid equivalent to oral prednisolone 1 mg/kg per day, starting one day before the infusion, for 30 days (see the stop rules and safety sections below).

Ask: "Which of these therapies can my child start the soonest, and what exact dose and schedule are you planning?"

Stop rules — the numbers that pause or stop a treatment. Every SMA medicine has specific checkpoints where the team pauses, delays, or stops it. Ask for these in writing so you know what is being watched.

The Zolgensma steroid is guided by liver numbers, not the calendar. The FDA label directs at least 30 days of prednisolone starting one day before the infusion, and to continue it — rather than taper — while liver enzymes (ALT/AST) stay elevated; the taper begins only once liver function is unremarkable, and liver function is monitored for at least 3 months.
Ask: "What ALT or AST number lets us begin the steroid taper, and what number means we go back up?"
Spinraza doses can be held for blood results. The FDA label advises checking platelet count and clotting (coagulation) tests before each intrathecal dose, because low platelets and bleeding problems have occurred; a dose may be delayed if these are abnormal.
Ask: "What platelet or clotting result would make you postpone a Spinraza dose?"
Evrysdi should be paused for pregnancy. There is no routine blood-test stop rule, but the FDA label calls for effective contraception and warns of possible harm to a pregnancy; discuss when to stop it if pregnancy is planned.

What it is: A one-time intravenous (IV) infusion that delivers a working copy of the SMN1 gene to motor neurons using an inactivated virus (AAV9) as a carrier. The infusion takes about an hour.

Who it’s for: Children under 2 years old with SMA. Most often used in babies under about 13.5 kg (the weight at which most centers stop offering it). Pre-treatment testing checks for anti-AAV9 antibodies that would block the therapy.

What to expect afterward:

An oral steroid (prednisolone) is given before the infusion and continued for at least 2 months, then tapered, to manage immune response and protect the liver.
Weekly bloodwork for at least the first month to monitor liver enzymes, platelets, and kidney markers.
Strict avoidance of live vaccines during steroid treatment.
Rare but serious risks include liver injury, low platelet counts (which can affect bleeding), and a rare blood clotting disorder called thrombotic microangiopathy (TMA). Serious liver injury is the basis of Zolgensma's FDA boxed warning (its most serious warning) — acute liver failure, including rare deaths, has been reported — which is why the steroid and the close liver-enzyme monitoring above are essential.

Cost: List price near $2.1 million per dose in the U.S. — the highest list price of any approved drug. It is usually covered by insurance for eligible patients, but the prior authorization process is intensive.

Long-term data: Five-year follow-up from the original Zolgensma trials shows that motor function gains are sustained in most children, and many pre-symptomatically treated children are walking independently.

What it is: The same SMN1 gene therapy as Zolgensma, but delivered intrathecally (into the spinal fluid by lumbar puncture) instead of by IV infusion. The intrathecal route lets the therapy reach motor neurons effectively in larger, older patients, for whom the IV dose is impractical.

Who it’s for: Children 2 years and older, teens, and adults with SMA (confirmed SMN1 mutation). It is the first and only one-time gene replacement therapy approved for this broader, older population — previously, gene therapy was limited to infants under 2 years (IV Zolgensma). It uses a fixed dose that does not need adjustment for age or weight.

Regulatory status: FDA-approved on November 24, 2025 (Novartis). Pre-treatment testing for anti-AAV9 antibodies still applies, as with IV gene therapy.

What to expect: As with other AAV9 gene therapies, an oral steroid is given around the time of treatment and monitoring for liver enzymes, platelets, and signs of thrombotic microangiopathy is required. The intrathecal procedure is performed by clinicians experienced with lumbar puncture; severe scoliosis or spinal fusion may require image guidance.

This is a newly approved option — discuss eligibility, anti-AAV9 antibody status, and how it compares with Spinraza and Evrysdi with your SMA specialist.

What it is: An antisense oligonucleotide (ASO) — a small piece of synthetic genetic material — that nudges the SMN2 gene to produce more functional SMN protein. It is given directly into the fluid around the spinal cord by lumbar puncture (spinal tap).

Dosing schedule: Four loading doses over about two months, then a maintenance dose every 4 months for life. A new higher-dose regimen was FDA-approved in March 2026 (two 50 mg loading doses two weeks apart, then 28 mg every 4 months) based on the DEVOTE study; people already on the original 12 mg dose can switch with a single higher dose. Ask your neurologist whether the higher-dose schedule is right for you.

Who it’s for: All ages, all types of SMA. It is the only therapy with the broadest age range, including adults.

What to expect:

Each dose requires a clinic visit, sometimes with sedation for young children.
In children and adults with severe scoliosis or spinal fusion, the lumbar puncture may need to be done with CT or ultrasound guidance, sometimes through a special spinal approach.
Side effects are usually mild — headache, back pain after the procedure. Long-term safety is well-established with over a decade of clinical experience.

Cost: Approximately $750,000 in the first year (loading doses), then $375,000 per year for maintenance, before negotiated discounts.

Long-term data: Extensive real-world data, including in adults, shows sustained motor stability or improvement and excellent safety over many years.

What it is: An oral liquid medication that, like Spinraza, modifies SMN2 to produce more SMN protein. Unlike the other two therapies, it reaches the entire body — not just motor neurons — and is taken daily at home.

Who it’s for: Adults and children with SMA, including infants from birth.

What to expect:

Dosed by weight and age, given once daily as a liquid (usually mixed with a small amount of food or water).
No procedures, no infusions, no clinic visits for administration.
Common side effects: diarrhea, fever, rash, mouth ulcers. Most are mild.
Requires a specialty pharmacy and refrigerated storage in some forms.
Drug interaction warnings exist for some medications — always tell every prescriber that your child or you take risdiplam.
Pregnancy precautions apply: both men and women of reproductive age should discuss contraception, because risdiplam may affect fertility and fetal development.

Cost: Approximately $340,000 per year for adults (weight-dependent), before negotiated discounts.

Long-term data: The SUNFISH and FIREFISH trials and their long-term extensions show sustained motor improvement or stability in patients across SMA types and ages.

There is no universal “best” therapy. The decision typically weighs:

Age and weight — IV Zolgensma is typically restricted to children under 2 and roughly under 13.5 kg. Since November 2025, the intrathecal version (Itvisma) extends one-time gene therapy to patients 2 years and older, including teens and adults.
Anti-AAV9 antibody status — If a child has antibodies against the AAV9 virus used in Zolgensma, gene therapy is not an option.
Spinal anatomy — Severe scoliosis or spinal fusion can make Spinraza injections technically challenging.
Travel and logistics — Spinraza requires clinic visits every 4 months; Evrysdi is daily at home; Zolgensma is one-time.
Family preference — Some families prefer the “one and done” nature of gene therapy; others prefer the long track record of Spinraza or the convenience of Evrysdi.
Insurance coverage — Each insurer has different prior authorization criteria for each therapy.

Some families ultimately use combination therapy — for example, Zolgensma followed by Spinraza or Evrysdi. This is increasingly common but remains off-label and should be discussed thoroughly with your specialist.

The SMA treatment landscape is rapidly evolving. Important investigational agents to know about:

Apitegromab — A monoclonal antibody that targets myostatin (a protein that limits muscle growth) to strengthen muscle directly, used in addition to an SMN-targeted therapy. The Phase 3 SAPPHIRE trial in non-ambulatory children and adults with SMA Type 2 or 3 met its primary endpoint of improved motor function. As of May 2026, apitegromab is not yet FDA-approved: the FDA issued a Complete Response Letter in September 2025 related to manufacturing facility observations (not safety or efficacy), and Scholar Rock resubmitted the application in March 2026. U.S. and European launches are anticipated in 2026 if approval is granted.
Combination therapy — Real-world use of Zolgensma followed by Spinraza or Evrysdi is expanding, with growing safety and efficacy data.
Next-generation gene therapies — Several biotech companies are developing AAV-based gene therapies designed for older or heavier patients, and intrathecal delivery approaches that could expand access beyond Zolgensma’s current age and weight limits.
SMN-independent strategies — Therapies targeting downstream consequences of motor neuron disease, including muscle and neuromuscular junction interventions, are in earlier trials.

Talk to your specialist about ongoing clinical trials — participation can be an option for some patients.

Given my child’s age, weight, and SMN2 copy number, which therapies are options?
What are the chances my child has anti-AAV9 antibodies, and when will that be tested?
How quickly do we need to choose — and start — treatment?
What are the realistic motor expectations with each therapy?
Is combination therapy something we should discuss now, or revisit later?
Are there clinical trials we should consider?
If apitegromab is approved later this year, how would it fit in?

Clinical Trials

Clinical trials have transformed SMA from a fatal infant disease into a treatable condition — and the next generation of trials aims to push outcomes further. Participation in a clinical trial can provide access to cutting-edge therapies and contribute to knowledge that benefits the entire SMA community.

SAPPHIRE (NCT05156320) — Phase 3 trial of apitegromab (anti-myostatin antibody) as add-on therapy in non-ambulatory patients with SMA Types 2 and 3 on background SMN-targeted therapy. Met its primary motor function endpoint. BLA resubmitted March 2026; approval anticipated 2026.
TOPAZ (NCT03921528) — Phase 2 active-treatment study of apitegromab in patients with Type 2 and Type 3 SMA, now with over 48 months of long-term safety and efficacy follow-up. This proof-of-concept study provided the foundation for the Phase 3 SAPPHIRE trial.
RAINBOWFISH (NCT03779334) — Open-label study of risdiplam in pre-symptomatic infants diagnosed through newborn screening. Demonstrated sustained motor milestones consistent with typical development.
SHINE (NCT02594124) — Long-term open-label extension of nusinersen, providing over 7 years of follow-up data on safety and motor function in patients who initially participated in ENDEAR or CHERISH.
Zolgensma Long-Term Follow-Up Study (NCT04042025) — Ongoing study tracking motor function, safety, and durability of gene therapy outcomes in patients treated with onasemnogene abeparvovec (Zolgensma) for up to 15 years.

These are the studies that actually changed SMA care. Each has a national registry ID (an “NCT number”) you can type into ClinicalTrials.gov to read the official record. Status is as of May 2026.

Study	Therapy	Who it studied	What it showed	Registry ID
ENDEAR	Spinraza (nusinersen)	Infants with Type 1 SMA	The pivotal infant trial; stopped early once benefit was clear, and babies moved into the SHINE extension. Led to the first FDA approval (December 2016).	NCT02193074
CHERISH	Spinraza (nusinersen)	Later-onset (Type 2) children	Meaningful motor gains vs. sham in children who could sit but not walk.	NCT02292537
NURTURE	Spinraza (nusinersen)	Pre-symptomatic babies (2–3 SMN2 copies), treated by 6 weeks of age	All treated infants were alive without permanent ventilation at multi-year follow-up; most sat and walked — the case for treating before symptoms.	NCT02386553
SHINE	Spinraza (nusinersen)	Long-term extension of ENDEAR/CHERISH	Over 7 years of safety and durability data.	NCT02594124
DEVOTE	Higher-dose Spinraza	Infants, children, adults	Supported the higher-dose regimen (50 mg loading, 28 mg maintenance) FDA-approved March 2026.	NCT04089566
RESPOND	Spinraza after Zolgensma	Children with residual weakness after gene therapy	Studied adding nusinersen when gene therapy alone left unmet need.	NCT04488133
FIREFISH	Evrysdi (risdiplam)	Infants with Type 1 SMA	Many treated infants sat unsupported and survived without permanent ventilation — outcomes not seen in the natural history of untreated Type 1.	NCT02913482
SUNFISH	Evrysdi (risdiplam)	Type 2/3, ages 2–25	Improved motor function vs. placebo; basis for the broad Evrysdi approval.	NCT02908685
JEWELFISH	Evrysdi (risdiplam)	People previously on other SMA drugs	Safety/tolerability in patients switching from nusinersen or gene therapy.	NCT03032172
RAINBOWFISH	Evrysdi (risdiplam)	Pre-symptomatic newborns	Most reached motor milestones on a typical schedule when started early.	NCT03779334
STR1VE-US	Zolgensma (onasemnogene)	Symptomatic Type 1 infants (US)	Pivotal gene-therapy trial: survival and motor milestones far beyond untreated natural history.	NCT03306277
STR1VE-EU	Zolgensma (onasemnogene)	Symptomatic Type 1 infants (Europe)	Confirmed STR1VE-US findings in a European cohort.	NCT03461289
SPR1NT	Zolgensma (onasemnogene)	Pre-symptomatic babies with 2–3 SMN2 copies	Most 2-copy babies sat independently; many 3-copy babies walked on a typical timeline.	NCT03505099
STEER	Itvisma (intrathecal onasemnogene)	Type 2 children age 2 and older	The trial behind the 2025 approval that extended one-time gene therapy beyond infancy.	NCT05089656
SAPPHIRE	Apitegromab (add-on)	Non-ambulatory Type 2/3 on an SMN drug	Met its motor endpoint as an add-on; FDA decision pending after a 2026 resubmission.	NCT05156320
MANATEE	GYM329 + risdiplam (add-on)	People on background risdiplam	Ongoing study of a muscle-targeted antibody stacked on an SMN therapy.	NCT05115110

Ask: "Are any of these studies — or their long-term extensions — open at a center near us, and would my child be eligible?"

ClinicalTrials.gov — Search for “spinal muscular atrophy” and filter by age, location, and recruiting status.
Cure SMA Clinical Trial Finder (curesma.org) — Patient-friendly search tool maintained by the leading SMA advocacy organization.
TREAT-NMD Global Registry (treat-nmd.org) — International patient registry that connects families to research opportunities worldwide.
Your neuromuscular specialist — Ask about trials at your next clinic visit. Academic centers like the University of Utah and Primary Children’s Hospital often participate in SMA trials.
MDA Clinical Trial Finder (mda.org) — Another searchable database covering neuromuscular disease trials including SMA.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is as important as knowing what does. These therapies were tested in rigorous clinical trials or were once standard care but are no longer recommended for SMA.

Olesoxime (Roche/Trophos) — A cholesterol-like neuroprotective compound that showed promise in a Phase 2 trial but failed to demonstrate meaningful motor function improvement in the Phase 2/3 extension study in SMA Types 2 and 3. Roche discontinued development in 2018. FAILED
Valproic acid and other HDAC inhibitors — Multiple trials of valproic acid, phenylbutyrate, and hydroxyurea tested the hypothesis that histone deacetylase inhibition could upregulate SMN2 expression. Several controlled trials showed no clinically meaningful motor benefit, and valproic acid carries metabolic and hepatic side effects. These are no longer recommended for SMA treatment. DE-ADOPTED
Creatine — Studied in a placebo-controlled trial for SMA Types 2 and 3. No significant improvement in motor function or pulmonary outcomes. FAILED
Gabapentin — Tested in SMA Types 2 and 3 in controlled trials. No significant motor benefit demonstrated. FAILED
Riluzole — Approved for ALS, riluzole was studied in SMA but did not show evidence of motor neuron protection or clinical improvement in SMA patients. FAILED
Taldefgrobep alfa (Biohaven) — A muscle-targeted (anti-myostatin/activin) drug tested as an add-on. The Phase 3 RESILIENT trial (NCT05337553) did not meet its primary motor endpoint at week 48, and the company discontinued the SMA program in 2024. A cautionary example that not every muscle-directed add-on succeeds — which is why the apitegromab data matter. FAILED
Branaplam (Novartis) — An oral SMN2 splicing modifier studied in Type 1 SMA (NCT02268552) around the same time as risdiplam. Novartis stopped its SMA development to focus on already-approved options; the molecule was later explored in Huntington disease and then discontinued there too. DE-ADOPTED
Stem cell transplantation (unregulated) — Some families have sought stem cell treatments at overseas clinics not associated with regulated clinical trials. No controlled evidence supports this approach for SMA, and the risks include infection, immune reactions, and financial exploitation. Regulated stem cell research for motor neuron diseases is ongoing but has not yet yielded an approved therapy. WITHDRAWN

Multidisciplinary Care: Everything That Goes With SMN Therapy

Even with the most effective SMN-targeted treatment, comprehensive care across multiple specialties is essential. SMA affects more than motor neurons — it affects breathing, swallowing, nutrition, bones, joints, and energy. A coordinated team helps you stay ahead of complications before they become emergencies.

The hidden curriculum. Families often spend the first months focused entirely on disease-modifying therapy. The team that supports your child or yourself over the years — pulmonologist, physical therapist, occupational therapist, nutritionist, orthopedist — matters just as much for daily quality of life.

Ask: "What breathing and feeding checks does my child need now, and at what point would you consider a sleep study, a cough-assist machine, or a feeding-tube discussion?"

Weak respiratory muscles are the leading source of serious complications in SMA. Care typically involves:

Sleep studies (polysomnography) to look for low oxygen or high carbon dioxide overnight, when respiratory weakness shows up first.
Non-invasive ventilation (BiPAP) — A small mask worn at night that supports breathing without a breathing tube. Often the first major respiratory intervention.
Cough assist devices — Help clear secretions from the lungs when the natural cough is too weak. Critical during respiratory infections.
Suction machines at home for managing oral secretions.
Vaccinations — RSV prophylaxis (palivizumab or nirsevimab for eligible infants), influenza, COVID-19, and pneumococcal vaccines are especially important.
Tracheostomy and long-term ventilation — In severe cases, especially historically untreated SMA Type 1, an extended decision-making conversation. Less commonly needed in pre-symptomatically treated children today.

Many families learn to use the cough assist and BiPAP themselves at home. The respiratory therapist who trains you is one of the most important members of your team.

Weakness can make feeding difficult, increase the risk of choking and aspiration (food or liquid going into the lungs), and lead to either undernutrition or, in less mobile children, excess weight gain. Expect ongoing involvement of:

Speech and swallow therapists — Evaluate the safety of eating by mouth and recommend feeding strategies.
Dietitians — Track growth and adjust calorie, protein, and micronutrient targets. Children with SMA often have unusual body composition (less muscle, sometimes more fat for their weight).
Gastrostomy tube (G-tube) decisions — A small feeding tube placed through the abdomen into the stomach can be life-changing for children who cannot eat enough safely by mouth. This does not have to be permanent and is often reversible if feeding skills improve.
Bone health — Vitamin D, calcium, and (in some cases) bisphosphonate treatments to reduce fracture risk, which is elevated in SMA.

Without normal muscle pull, bones and joints develop differently. The orthopedic team monitors and treats:

Scoliosis — Sideways curvature of the spine. Common in non-ambulatory children. Treatment ranges from bracing to growing rods (in young children) to spinal fusion (typically after age 10–12). The era of SMN-targeted therapy is changing scoliosis trajectories — many treated children develop milder curves later than historical cohorts.
Hip subluxation and dislocation — Especially in non-walkers. Often managed conservatively unless painful.
Contractures — Tightness of joints from limited movement. Stretching, splinting, and (rarely) surgery can help.
Custom seating — A properly fitted wheelchair or seating system is not just about mobility; it’s about spinal alignment, breathing, comfort, and skin health.

Children with severe scoliosis or spinal fusion who need ongoing Spinraza may require special imaging or alternative approaches for intrathecal injections. This is one of the key practical considerations in long-term therapy planning.

PT and OT are the through-line of life with SMA. The goals shift over time:

In infants and toddlers — Encouraging head control, sitting, transitions, and exploration. Pre-symptomatically treated babies may pursue typical milestones.
In school-age children — Maintaining strength, optimizing function, supporting transitions between sitting, standing, and walking (with or without assistive devices).
In teens and adults — Preserving independence, energy conservation, adaptive equipment, fall prevention, exercise tailored to fatigue and respiratory limits.

Aquatic therapy can be especially helpful — the buoyancy of water lets people move in ways that aren’t possible on land.

When should we have our first sleep study? How often after that?
Do we have the right cough assist and suction equipment, and is everyone in the household trained on it?
Is my child’s growth on track for someone with SMA, or are we under- or over-feeding?
When should we expect to discuss a G-tube, if ever?
How is the spine looking? Do we need a brace? When will we consider surgery?
What does an ideal PT/OT schedule look like for us right now?
If we live far from a specialty center, can some of this care happen locally?

Living with SMA: Daily Life, School, Work, and Adulthood

SMA used to be a diagnosis discussed almost entirely in pediatric terms. Today, with the first generation of treated patients growing up, “living with SMA” means very different things for a pre-symptomatically treated toddler, a school-age child who uses a power wheelchair, a teenager planning for college, and an adult navigating work and family.

Caregiver note. If you are reading this as a parent or caregiver: your wellbeing matters. Burnout among SMA caregivers is real and common. Asking for — and accepting — help, respite, and mental health support is a clinical-grade intervention for your family.

Children with SMA almost always qualify for school accommodations under the Individuals with Disabilities Education Act (IDEA, via an Individualized Education Plan or IEP) or Section 504 of the Rehabilitation Act. Common supports:

Accessible classrooms and bathrooms
Personal care attendants
Adapted physical education
Accessible technology and seating
Excused absences for clinic visits and medical care
Adapted transportation
Modified gym, recess, and field-trip plans

Many parents recommend requesting an IEP evaluation before kindergarten and revisiting it annually. School districts in Utah and elsewhere have specialists who handle complex medical IEPs; ask the district directly.

The financial side of SMA is often as taxing as the medical side. Practical advice from families who have been through it:

Get a hospital social worker and a financial navigator early. Most academic neuromuscular centers have one assigned to SMA families.
Manufacturer patient assistance programs — Each of Zolgensma (Novartis), Spinraza (Biogen), and Evrysdi (Genentech) has a dedicated patient support program with case managers.
Specialty pharmacies handle high-cost drugs differently than retail pharmacies; expect a learning curve.
Medicaid waivers — Many states, including Utah, have waivers that provide additional support to children with significant disabilities regardless of household income. Eligibility rules are complex; a social worker can guide you.
Out-of-pocket maximums — Once met for the year, additional covered care is paid 100% by insurance. This affects timing of major procedures.
Document everything. Keep a folder with all insurance correspondence, EOBs (Explanation of Benefits), and prior authorization letters.

One of the newer challenges in SMA is what happens after a child outgrows pediatric neurology. Adult neuromuscular medicine is a smaller specialty, and not every adult neurologist is comfortable managing the long-term complications of SMA. Tips:

Start the transition conversation by age 14–16, not at 18.
Ask your pediatric team for an adult neuromuscular referral well in advance.
The MDA Care Center model at academic centers (including the University of Utah) sees both children and adults.
Keep all genetic test results, prior authorization letters, motor function scores (CHOP-INTEND, HFMSE, RULM), and imaging in your possession.

SMA is a marathon for everyone in the family. Topics that come up over the years:

Anxiety and depression in older children, teens, and adults with SMA
Sibling experience — brothers and sisters of children with significant medical needs benefit from their own outlets and time
Marital strain in parents of medically complex children — couples therapy is not a sign of failure
Grief that doesn’t fit traditional categories — for the path that wasn’t taken, even when the current path is going well
Identity in young adults with SMA — disability identity, dating, work, independence

Most major neuromuscular clinics have psychologists or social workers experienced with SMA families. Cure SMA also offers peer-support networks that families consistently rate as one of the most valuable resources.

Does our center have a social worker, financial navigator, or family liaison?
What Medicaid waivers or state programs might we be eligible for?
Who handles the transition to adult care, and when should we start?
Are there local Cure SMA or MDA family events?
What mental health support is available for me as a caregiver?

Support & Resources

Where to find people, information, and care — locally and globally.

Cure SMA (curesma.org) — The primary U.S. patient advocacy organization. Newly diagnosed family packets, research updates, annual conferences, and chapter events.
Muscular Dystrophy Association (MDA) (mda.org) — Funds Care Centers (including at the University of Utah), summer camps, equipment loans, and research.
SMA Europe (sma-europe.eu) — Federation of European SMA patient organizations.
SMA Foundation (smafoundation.org) — Research-focused.
TREAT-NMD Neuromuscular Network (treat-nmd.org) — International registry and research consortium.
SMA REACH (UK-based) — Pediatric SMA natural history and outcomes network.

University of Utah Neuromuscular Program / MDA Care Center — Multidisciplinary care for children and adults with SMA. The hub for SMN-targeted therapy administration in the Intermountain West.
Primary Children’s Hospital (Salt Lake City) — Pediatric neuromuscular clinic with respiratory, orthopedic, and rehabilitation services.
Intermountain Health — Pediatric neurology referral pathways and post-acute services across the region.
Utah Newborn Screening Program — Utah was the first U.S. state to add SMA to its newborn screen (since January 2018); the program coordinates urgent confirmatory testing and specialist referral.
ARUP Laboratories (Salt Lake City) — National reference lab for SMN1/SMN2 genetic testing.
Cure SMA Rocky Mountain Chapter — Regional family events and local support.

It is honest to acknowledge that SMA care looks very different across the world:

Newborn screening for SMA is universal in the U.S. and Germany; widespread in Australia, Belgium, Taiwan, and Italy; piloting in Japan, the UK, Canada, France, and Korea; and largely unavailable in low- and middle-income countries.
Zolgensma is reimbursed in fewer than half the countries where SMA care exists; some countries have used managed-access “lottery” programs.
Spinraza and Evrysdi have broader access through various reimbursement agreements, but in many regions only specific SMA types or ages qualify.
Intrathecal infrastructure for Spinraza is limited in some areas, particularly outside major cities.
In some Middle Eastern, North African, and South Asian populations with higher consanguinity, SMA prevalence is also higher — making the access gap especially painful.

If you are caring for an international family member with SMA, contact SMA Europe, the regional SMA federation, or TREAT-NMD for region-specific guidance.

Things to track in a notebook or app:

Medication doses, times, missed doses
BiPAP and cough assist use
Weight, height (or arm span if scoliosis is severe)
Sick days, fevers, hospitalizations
Motor milestones or changes in function
Equipment serial numbers and last-service dates

Red flags — call your team or seek care:

New weakness or loss of a skill that was previously present
Increased work of breathing, especially at rest or during sleep
Choking or coughing with feeds, weight loss, or feeding refusal
Fever with respiratory symptoms in a child with SMA — lower threshold for urgent evaluation than for typical children
For children on or after Zolgensma: yellowing of the skin or eyes, vomiting, bruising, dark urine
For anyone on Evrysdi: severe diarrhea, rash, mouth sores

Going-to-the-hospital bag for SMA emergencies:

Current medication list (with doses and times)
Copy of the SMA genetic test result
Recent clinic notes, especially respiratory and motor assessments
Equipment list (BiPAP settings, cough assist settings)
Emergency care plan letter from your SMA specialist, if you have one
Contact information for your neuromuscular team

Can you write us a one-page emergency care plan for hospital visits?
Do you participate in Cure SMA or TREAT-NMD registries? Should we?
Are there clinical trials open at your center we should know about?
Can we have direct contact information — nurse line, secure messaging — for urgent questions?
Who can we call after hours if something is concerning but not an emergency?

Disclaimer. This guide is for educational purposes only and is not a substitute for medical advice. Always discuss diagnosis, treatment options, and care decisions with your own healthcare team. Drug approvals, prices, access programs, and clinical evidence change over time; verify time-sensitive details (such as the regulatory status of investigational therapies like apitegromab) with your specialist or the FDA. The information presented here reflects best available evidence and standards of care as of May 2026.

Specialty Centers

SMA is a complex neuromuscular disease best managed at centers with dedicated neuromuscular programs, experience with SMN-targeted therapies, and multidisciplinary teams. Below are centers with established SMA programs across regions.

University of Utah Neuromuscular Program & MDA Care Center — Salt Lake City, UT. Multidisciplinary SMA care for children and adults; DMT administration including intrathecal nusinersen; neurology, pulmonology, PT/OT, genetics, and social work. (801) 585-7575
Primary Children’s Hospital (Intermountain Health) — Salt Lake City, UT. Pediatric neuromuscular clinic; respiratory care with NIV and cough assist; pediatric orthopedic spine team; rehabilitation services. (801) 662-1000
Intermountain Health Pediatric Neurology — Network-wide referral pathways across Utah, Idaho, and Nevada for pediatric and adult neurology including SMA.
Children’s Hospital Colorado — Aurora, CO. MDA Care Center with pediatric neuromuscular program; SMA gene therapy and intrathecal therapy administration. (720) 777-1234
Phoenix Children’s Hospital — Phoenix, AZ. Neuromuscular program with SMA-specific multidisciplinary clinic.

Boston Children’s Hospital / Harvard — Boston, MA. One of the largest pediatric SMA programs in the U.S.; participated in pivotal Zolgensma and Spinraza trials. (617) 355-6000
Columbia University Irving Medical Center — New York, NY. SMA Clinical Research Center; home to investigators in the ENDEAR, CHERISH, and NURTURE nusinersen trials. (212) 305-6942
Nationwide Children’s Hospital — Columbus, OH. Where the first Zolgensma gene therapy was developed and administered; Jerry Mendell Center for Gene Therapy. (614) 722-2000
Stanford University / Lucile Packard Children’s Hospital — Palo Alto, CA. Neuromuscular program with extensive SMA clinical trial participation. (650) 723-5711
Children’s Hospital of Philadelphia (CHOP) — Philadelphia, PA. Developed the CHOP-INTEND motor function scale used worldwide for SMA assessment. (215) 590-1000

VA Salt Lake City Health Care System — Salt Lake City, UT. Neurology service with access to the University of Utah neuromuscular program for complex neuromuscular conditions including adult SMA. (801) 582-1565
VA Puget Sound Health Care System — Seattle, WA. Neuromuscular disease program affiliated with University of Washington. (206) 762-1010
VA Boston Healthcare System — Boston, MA. Neurology service with referral pathway to Harvard-affiliated neuromuscular specialists.

Veterans with SMA can be referred through the VA Community Care program to academic neuromuscular centers when specialized SMA expertise is not available within the local VA system.

The Hospital for Sick Children (SickKids) — Toronto, ON. Leading Canadian pediatric neuromuscular center; participated in SMA gene therapy trials.
Montreal Children’s Hospital (McGill) — Montreal, QC. Pediatric neuromuscular disease program with SMA expertise.
BC Children’s Hospital — Vancouver, BC. Western Canada referral center for pediatric neuromuscular conditions including SMA.
Alberta Children’s Hospital — Calgary, AB. Neuromuscular program serving the Prairie provinces.

Cure SMA — the leading SMA-specific organization: education, a care-center network, newly-diagnosed support, financial-assistance and equipment resources, and a national helpline at 1-800-886-1762 (info@curesma.org). An excellent first call after a diagnosis.
Muscular Dystrophy Association (MDA) — MDA Care Centers nationwide and a resource center reachable at 1-833-275-6321 (833-275-6321); support, clinics, and information on SMA and other neuromuscular diseases.
SMA Foundation and nNALS / Cure SMA registries — patient registries that connect families to clinical trials and research; ask your care team or Cure SMA about enrolling.
National Institute of Neurological Disorders and Stroke (NINDS) — ninds.nih.gov, for trustworthy disease information; and ClinicalTrials.gov for current studies.
Genetic & family support — because SMA is inherited (carrier frequency ~1 in 40–50), genetic counseling is valuable for families; the U.S. carrier-screening and newborn-screening programs (SMA is on the federal Recommended Uniform Screening Panel) have transformed early diagnosis.

Tip: when you call a center, ask specifically whether they administer the SMN-targeted therapies you may need (intrathecal nusinersen, the one-time gene therapy onasemnogene abeparvovec for eligible infants, or oral risdiplam) and whether they run a multidisciplinary SMA clinic, since not every neurology office offers the full program.

Great Ormond Street Hospital (GOSH) — London, UK. One of Europe’s largest pediatric neuromuscular programs; Dubowitz Neuromuscular Centre.
Essen University Hospital — Essen, Germany. Leading European center for SMA; published extensive data on newborn screening outcomes.
Istituto Neurologico Carlo Besta — Milan, Italy. Italian SMA reference center; iSMAc registry.
Royal Children’s Hospital Melbourne / Murdoch Children’s Research Institute — Melbourne, Australia. Australian NBS outcome studies and SMA therapy access programs.
National Center of Neurology and Psychiatry (NCNP) — Tokyo, Japan. Japanese SMA reference center with PMDA-approved therapy administration.

Glossary

SMA (Spinal Muscular Atrophy) — A genetic disorder that causes motor neurons in the spinal cord to break down, leading to progressive muscle weakness and difficulty with movement, breathing, and swallowing.
SMN1 (Survival Motor Neuron 1) — The primary gene responsible for producing the SMN protein, which motor neurons need to survive. SMA is caused by a missing or non-working copy of this gene.
SMN2 (Copy Number) — A “backup” gene that makes a small amount of functional SMN protein. People with more copies of SMN2 generally have milder forms of SMA, so copy number helps predict disease severity.
Motor Neuron — A nerve cell in the brain or spinal cord that sends signals to muscles, telling them to move. In SMA, these cells gradually deteriorate because they lack enough SMN protein.
NBS (Newborn Screening) — A routine blood test done shortly after birth that can detect SMA before symptoms appear. Early detection allows treatment to begin as soon as possible, which greatly improves outcomes.
Nusinersen (Spinraza) — The first FDA-approved treatment for SMA. It is an antisense oligonucleotide injected into the spinal fluid that helps the SMN2 gene produce more functional SMN protein.
Onasemnogene abeparvovec (Zolgensma / Itvisma) — A one-time gene therapy that delivers a working copy of the SMN1 gene into motor neurons using a harmless virus (AAV9) as a delivery vehicle. The original IV formulation (Zolgensma) is for children under two; the intrathecal formulation (Itvisma, FDA-approved November 2025) extends gene therapy to patients 2 years and older.
Risdiplam (Evrysdi) — An oral liquid medication taken daily at home that helps the SMN2 gene produce more functional SMN protein. It is approved for patients of all ages with SMA.
AAV9 (Adeno-Associated Virus Serotype 9) — A harmless virus used as a delivery vehicle in Zolgensma gene therapy. It can cross from the bloodstream into the nervous system, carrying a working copy of the SMN1 gene to motor neurons.
Intrathecal — A method of delivering medication directly into the spinal fluid through a lumbar puncture (spinal tap). Spinraza is given this way to reach the motor neurons in the spinal cord.
CHOP-INTEND — A clinical assessment scale used to measure motor function in infants with SMA. Higher scores indicate better motor ability, and improvements on this scale help track how well treatment is working.
HFMSE (Hammersmith Functional Motor Scale Expanded) — A standardized test used to measure motor function in children and adults with SMA who can sit. It evaluates abilities like sitting, rolling, and standing to track disease progression and treatment response.
Apitegromab — An investigational (not yet approved) antibody therapy being studied as an add-on treatment for SMA. It works by blocking myostatin, a protein that limits muscle growth, with the goal of improving muscle strength beyond what SMN-targeted therapies achieve alone.
SMA Type 1 — The most severe form of SMA, appearing before six months of age. Without treatment, affected infants cannot sit independently and historically had very limited life expectancy. Early treatment has dramatically changed outcomes.
SMA Type 2 — An intermediate form of SMA with symptom onset between 6 and 18 months. Children can learn to sit but typically cannot walk independently without treatment. Respiratory and orthopedic care are important parts of management.
SMA Type 3 — A milder form of SMA with symptom onset after 18 months. Individuals can walk at some point in their lives, though some may lose that ability over time. Life expectancy is generally normal.
SMA Type 4 — The mildest and rarest form of SMA, with symptom onset in adulthood (usually after age 30). It causes mild to moderate muscle weakness and does not typically affect life expectancy.
BiPAP (Bilevel Positive Airway Pressure) — A breathing support machine that delivers air pressure through a mask to help keep the airways open. Many people with SMA use BiPAP during sleep or rest to support weakened breathing muscles.
Cough Assist (Mechanical Insufflation-Exsufflation) — A device that helps clear mucus from the lungs by alternating positive and negative air pressure to simulate a strong cough. It is essential for people with SMA who have weak cough strength.
Scoliosis — An abnormal sideways curvature of the spine. Scoliosis is very common in SMA due to weak trunk muscles, and it can worsen over time, sometimes requiring bracing or surgery to protect breathing and comfort.
Bulbar Function — The ability to swallow, chew, speak, and manage saliva, controlled by nerves in the brainstem (bulbar region). Weakness in bulbar function is common in more severe SMA types and may require modified diets or feeding tube support.

Appendix A — Dosing Reference (so you can read the orders)

Your team sets and monitors every dose. These are the amounts written on FDA labels and infusion orders, so a prescription or pharmacy printout is easier to recognize. Figures below are from the U.S. FDA prescribing information (DailyMed) for Spinraza, Evrysdi, and Zolgensma, current as of May 2026.

Spinraza (nusinersen) — intrathecal

Original regimen (per FDA label): 12 mg per dose. Four loading doses at about day 0, day 14, day 28, and day 63, then 12 mg every 4 months for life. Supplied as a 12 mg/5 mL single-dose vial.
Higher-dose regimen (FDA-approved March 2026, from the DEVOTE trial): two 50 mg loading doses 14 days apart, then 28 mg every 4 months. New vial strengths are 50 mg/5 mL and 28 mg/5 mL. Someone already on the 12 mg schedule switches with a single 50 mg dose given at least 4 months after the last 12 mg dose.
Ask: "Are we on the 12 mg schedule or the newer 50 mg / 28 mg schedule, and why is that the right one for us?"

Evrysdi (risdiplam) — oral, once daily

Under 2 months: 0.15 mg/kg once daily.
2 months to under 2 years: 0.20 mg/kg once daily.
2 years and older, under 20 kg: 0.25 mg/kg once daily.
2 years and older, 20 kg or more: 5 mg once daily.
Supplied as a constituted oral solution at 0.75 mg/mL (a 2 mg dose is about 2.7 mL); a tablet form also exists for eligible patients. Give after a meal at about the same time each day; a water flush follows a feeding-tube dose.
Ask: "What is my child’s exact daily dose in milligrams and milliliters today, and when do we recalculate it for weight?"

Zolgensma (onasemnogene abeparvovec) — one-time IV gene therapy

A single weight-based IV dose for eligible children under 2 years.
Prednisolone 1 mg/kg per day by mouth starts one day before the infusion and continues for at least 30 days, then tapers based on liver enzymes (some children need IV methylprednisolone if the liver reacts).
Ask: "What weight are you dosing to, and what is the exact prednisolone plan — start date, daily milligrams, and when we taper?"

Supportive-care doses you may also see

Vitamin D (cholecalciferol): commonly 400 IU daily in infants and 600 IU to 1000 IU daily in older children for bone health; the exact amount is set from a blood level.
Apitegromab (investigational add-on): studied at 10 mg/kg and 20 mg/kg by IV every 4 weeks in the SAPPHIRE trial — listed so you recognize it, not because it is approved yet.

Appendix B — How treatments work together (and where they do not)

SMA care is not a single pill; it is a stack of interventions whose benefits combine. Understanding the intended synergy helps you see why the team asks you to keep up the “boring” parts even after a dramatic drug works.

SMN drug + early timing = the biggest synergy of all. The same medicine given pre-symptomatically after newborn screening produces far more benefit than the identical dose given after symptoms. The drug and the clock amplify each other.
SMN drug + physical/occupational therapy. Medication keeps motor neurons alive; therapy turns preserved neurons into real-world skills. The combined benefit is greater than either alone — a treated child still needs PT/OT to build sitting, standing, and walking.
SMN drug + apitegromab (a muscle-directed add-on, if approved). Apitegromab is being studied stacked on top of Spinraza or Evrysdi — the SMN drug protects the nerve, the antibody targets the muscle. SAPPHIRE tested exactly this stacking strategy; MANATEE (NCT05115110) is testing a similar muscle-targeted antibody combined with risdiplam.
Gene therapy followed by an SMN2 drug. Some families use Zolgensma first, then add Spinraza or Evrysdi if function plateaus. This combination is increasingly common but remains off-label; benefit is not yet proven in a randomized trial, so it should be a deliberate, documented decision with your specialist.
Respiratory + nutrition + orthopedic care. Good nutrition supports breathing muscles; good breathing support prevents the infections that cause weight loss; spinal support protects lung volume. These systems reinforce each other, which is why the team treats them together.

Ask: "Which parts of our plan are meant to work together, and what would we lose if we dropped the therapy or the equipment because the medicine seems to be working?"

Appendix C — Cost, Coverage & Assistance

SMA therapies are among the most expensive medicines in the world. The good news: for eligible patients, they are usually covered, and every manufacturer runs a support program. The list prices below are U.S. figures as of May 2026 and are what insurers negotiate down from — they are almost never what a covered family pays out of pocket.

Approximate U.S. list prices

Zolgensma (Novartis): about $2,100,000 as a one-time dose — the reason it is billed as a single medical-benefit claim, not a pharmacy prescription.
Spinraza (Biogen): about $750,000 in the first year (the loading doses) and about $375,000 per year thereafter, since each vial runs near $125,000 and year one uses six doses.
Evrysdi (Genentech): weight-based; commonly quoted near $100,000 per year in small children, around $200,000 per year at intermediate weights, and up to about $340,000 per year at adult weights.
Itvisma (Novartis, intrathecal gene therapy): a one-time gene-therapy price in the same order of magnitude as Zolgensma; confirm the current figure with the manufacturer program.

How these get paid

Zolgensma and other infused/gene therapies are usually billed under the medical benefit (for many patients on Medicare that is Part B; children are most often on commercial plans or Medicaid). Prior authorization is intensive but approval for eligible patients is common.
Evrysdi is a take-home drug billed under the pharmacy benefit through a specialty pharmacy.
Medicaid and state waivers — Many states, including Utah, offer disability waivers that help regardless of household income. A hospital social worker is the fastest route in.
Out-of-pocket maximum — once your plan’s annual maximum is met, covered care is paid at 100% for the rest of the year, which can affect the timing of a big procedure.

Manufacturer and nonprofit assistance (verify current terms when you call)

OneGene Program (Novartis, for Zolgensma/Itvisma) — case managers, benefits investigation, and copay/assistance navigation.
Biogen Support Services / Cobblestone (Spinraza) — dedicated case management and copay support for eligible commercially insured patients.
Genentech Access Solutions (Evrysdi) — benefits verification, copay assistance for eligible commercial patients, and referral to independent foundations.
Cure SMA — independent help understanding options; national helpline 1-800-886-1762.
Independent copay foundations (e.g., PAN Foundation, HealthWell, Good Days) — may help with cost-sharing when funds are open; eligibility is income-based.

Ask: "Can you connect us with the manufacturer support program and a financial navigator this week, and will our therapy be billed under the medical or the pharmacy benefit?"

Appendix D — Monitoring, red-line numbers, and stop rules

Ask your team to write these checkpoints down for you. Knowing the numbers turns a scary lab result into an expected part of the plan.

Zolgensma — liver. Liver enzymes (ALT/AST) are checked before the infusion, then weekly for at least the first month and closely for at least 3 months. The prednisolone is not tapered on a fixed calendar — the team holds the taper while ALT/AST stay elevated and only steps down once liver function looks normal. This is a formal stop/hold criterion tied to a number, not a date.
Ask: "What ALT or AST value pauses our steroid taper, and what value would send us back to a higher dose?"
Zolgensma — platelets and TMA. Platelet counts are watched in the days to weeks after infusion; a falling platelet count with anemia and kidney changes can signal thrombotic microangiopathy (TMA), which is a discontinue-current-plan-and-escalate situation.
Ask: "What platelet number would worry you, and what symptoms of TMA should send us to the ER?"
Spinraza — before each dose. The FDA label advises checking platelet count and clotting tests before every intrathecal dose; an abnormal result is a reason to delay that dose. Urine protein is also monitored over time.
Ask: "Which blood results would make you postpone my next Spinraza dose?"
Evrysdi — pregnancy stop rule. There is no routine blood-test threshold, but the label calls for effective contraception; the drug should be paused with medical guidance if pregnancy is planned or discovered, given the risk to a pregnancy.
Ask: "If we are planning a pregnancy, when and how do we stop risdiplam safely?"
When to reconsider any therapy. A treatment trial is worth revisiting if there is a clear, sustained loss of function despite good adherence, an unacceptable side effect, or a better-matched option becomes available. “Stopping” is rarely all-or-nothing in SMA — more often it means switching or adding.
Ask: "What sustained change in my child’s function would make you rethink this specific therapy?"

Appendix E — Scripts for the hardest conversations

Copy these, adapt them, and bring them to appointments. They are written so you can equip yourself without needing to be a clinician.

At diagnosis or a positive newborn screen

Ask: "Is the deletion of both SMN1 copies confirmed, and exactly how many SMN2 copies does my child have?"
Ask: "Are we still in the pre-symptomatic window, and how many days do we realistically have before treatment should start?"
Ask: "Given our copy number and weight, which of the approved therapies can start soonest?"

Choosing and starting therapy

Ask: "Has my child been tested for anti-AAV9 antibodies, and does the result open or close the gene-therapy option?"
Ask: "What are the realistic motor expectations with each therapy for a child like mine?"
Ask: "If we choose gene therapy, walk me through the steroid plan and the liver-monitoring schedule."
Ask: "Would you recommend combining therapies now, or keeping that option in reserve?"

Ongoing care and the multidisciplinary team

Ask: "When is our first sleep study, and what breathing numbers would trigger a cough-assist machine or nighttime BiPAP?"
Ask: "Is my child’s growth on track for SMA, or are we under- or over-feeding?"
Ask: "How is the spine looking, and at what curve angle do we discuss bracing or surgery?"
Ask: "If scoliosis or a spinal fusion makes lumbar punctures hard, what is our backup plan for Spinraza?"

Access, money, and logistics

Ask: "Can we meet a social worker and financial navigator before treatment starts?"
Ask: "Will this therapy be billed under my medical or my pharmacy benefit, and what is our expected out-of-pocket cost?"
Ask: "Which manufacturer or foundation assistance programs should we apply to, and can your team help with the paperwork?"

Adults and transitions

Ask: "I was diagnosed before these treatments existed — am I a candidate now, and who is the adult neuromuscular specialist you would send me to?"
Ask: "Who coordinates the move from pediatric to adult care, and when should we begin?"
Ask: "Can you write us a one-page emergency plan for hospital visits and after-hours calls?"

Appendix F — Sources & How to Verify This Guide

Dated so you can check each claim yourself. Regulatory status, prices, and trial results change — verify anything time-sensitive with your team or the primary source.

FDA prescribing information (DailyMed / Drugs@FDA): Spinraza (nusinersen) label, higher-dose update March 2026; Evrysdi (risdiplam) label; Zolgensma (onasemnogene abeparvovec) label with the boxed warning for acute serious liver injury; Itvisma label (approved November 2025).
Finkel et al., 2017 — ENDEAR nusinersen trial in infantile SMA, New England Journal of Medicine.
Mercuri et al., 2018 — CHERISH nusinersen trial in later-onset SMA, New England Journal of Medicine.
De Vivo et al., 2019 — NURTURE pre-symptomatic nusinersen study, Neuromuscular Disorders.
Mendell et al., 2017 — START phase 1 gene-therapy (AVXS-101/Zolgensma) trial, New England Journal of Medicine.
Day et al., 2021 — STR1VE-US onasemnogene abeparvovec trial, Lancet Neurology.
Baranello et al., 2021 — FIREFISH risdiplam trial in infants, New England Journal of Medicine.
Mercuri et al., 2022 — SUNFISH risdiplam trial in Type 2/3 SMA, Lancet Neurology.
Strauss et al., 2022 — SPR1NT pre-symptomatic onasemnogene abeparvovec study, Nature Medicine.
Darras et al., 2019 — nusinersen safety/pharmacology across the SMA program, Neurology.
Mendell et al., 2021 — long-term (5-year) follow-up after START gene therapy, JAMA Neurology.
Servais et al., 2024 — DEVOTE higher-dose nusinersen results supporting the 2026 label update.
Finkel et al., 2023 — TOPAZ apitegromab phase 2 extension, informing the SAPPHIRE phase 3 trial.
Vill et al., 2021 — German newborn-screening outcomes trial cohort, Journal of Neuromuscular Diseases.
Chien et al., 2023 — Taiwan newborn-screening 5-year real-world outcomes.
Cure SMA, 2024 — SMA newborn-screening implementation and care-standard resources.
NICE technology appraisals — TA588 (nusinersen), TA755 (onasemnogene abeparvovec), and risdiplam appraisals, UK, 2019–2021.
Mercuri et al., 2018 (Standards of Care, Parts 1 & 2) — consensus SMA care guideline, Neuromuscular Disorders.
Glascock et al., 2018; updated 2020 — SMA newborn-screening treatment algorithm by SMN2 copy number, Journal of Neuromuscular Diseases.
ACMG / ACOG carrier-screening guidance (Prior et al., 2011; updated statements) — population SMA carrier screening.
Cure SMA (curesma.org), MDA (mda.org), TREAT-NMD (treat-nmd.org) — patient organizations, registries, and care-center directories.
ClinicalTrials.gov — the primary record for every NCT number cited in this guide; the U.S. SMA newborn-screening panel (RUSP) addition dates from 2018.

A Research Guide for
SMA

⚡ Quick Start — If You Read Nothing Else

Understanding Spinal Muscular Atrophy

Diagnosis & Genetics: Understanding Your Test Results

SMN-Targeted Treatments: The Four Approved Therapies

Clinical Trials

Failed & De-Adopted Therapies

Multidisciplinary Care: Everything That Goes With SMN Therapy

Living with SMA: Daily Life, School, Work, and Adulthood

Support & Resources

Specialty Centers

Glossary

Appendix A — Dosing Reference (so you can read the orders)

Spinraza (nusinersen) — intrathecal

Evrysdi (risdiplam) — oral, once daily

Zolgensma (onasemnogene abeparvovec) — one-time IV gene therapy

Supportive-care doses you may also see

Appendix B — How treatments work together (and where they do not)

Appendix C — Cost, Coverage & Assistance

Approximate U.S. list prices

How these get paid

Manufacturer and nonprofit assistance (verify current terms when you call)

Appendix D — Monitoring, red-line numbers, and stop rules

Appendix E — Scripts for the hardest conversations

At diagnosis or a positive newborn screen

Choosing and starting therapy

Ongoing care and the multidisciplinary team

Access, money, and logistics

Adults and transitions

Appendix F — Sources & How to Verify This Guide

Important Safety Information: SMA Treatments

A Research Guide forSMA

⚡ Quick Start — If You Read Nothing Else

Understanding Spinal Muscular Atrophy

Diagnosis & Genetics: Understanding Your Test Results

SMN-Targeted Treatments: The Four Approved Therapies

Clinical Trials

Failed & De-Adopted Therapies

Multidisciplinary Care: Everything That Goes With SMN Therapy

Living with SMA: Daily Life, School, Work, and Adulthood

Support & Resources

Specialty Centers

Glossary

Appendix A — Dosing Reference (so you can read the orders)

Spinraza (nusinersen) — intrathecal

Evrysdi (risdiplam) — oral, once daily

Zolgensma (onasemnogene abeparvovec) — one-time IV gene therapy

Supportive-care doses you may also see

Appendix B — How treatments work together (and where they do not)

Appendix C — Cost, Coverage & Assistance

Approximate U.S. list prices

How these get paid

Manufacturer and nonprofit assistance (verify current terms when you call)

Appendix D — Monitoring, red-line numbers, and stop rules

Appendix E — Scripts for the hardest conversations

At diagnosis or a positive newborn screen

Choosing and starting therapy

Ongoing care and the multidisciplinary team

Access, money, and logistics

Adults and transitions

Appendix F — Sources & How to Verify This Guide

Important Safety Information: SMA Treatments

A Research Guide for
SMA